Samuel R. Wilson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Samuel R. Wilson has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
Jane Little
University of North Carolina School of Medicine Chapel Hill North Carolina USA
4 shared publications- Abraham Haimed
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
2 shared publications Alexa J. Siddon
YALE UNIVERSITY SCHOOL OF MEDICINE, NEW HAVEN, CONNECTICUT, United States
2 shared publicationsAmy Soni
Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, United States
2 shared publicationsChibuzo Ilonze
University of Alabama- Pediatric Sickle Cell comprehensive Lifespan Center, Birmingham, Alabama, United States
2 shared publicationsDavid Wichlan
Division of Hematology and Blood Research Center, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC
2 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by American Society of Hematology in Blood Advances
A Roadmap for Developing and Implementing Duffy Null-Specific Reference Intervals
The Duffy null variant is found in 10% of the United States population, and results in distinct absolute neutrophil counts (ANC) and white blood cell count (WBC) RIs. Investigators from twenty-three institutions completed a collaborative assessment of ANC and WBC in healthy Duffy-null pediatric and adult participants. This report summarizes a roadmap for developing and implementing Duffy-null RIs and infrastructure. Through consensus, we identified the following key themes: 1) Identifying Stakeholders and Funding, 2) Collecting Samples, 3) Testing for Duffy Status, 4) Implementing Duffy-Specific Policies and Tools, and 5) Educating Providers and Duffy-null individuals. Across themes, we outline challenges and opportunities relevant to the development and implementation of Duffy-null infrastructure. We provide examples from community and academic practice settings as well as sites with geographic, size, funding, and population diversity. This roadmap will support healthcare systems, hospitals, and laboratories in developing and implementing Duffy-specific infrastructure.
- 5 November 2026
- Published by American Society of Hematology in Blood Advances
Open AccessA Roadmap for Developing and Implementing Duffy Null-Specific Reference Intervals
The Duffy null variant is found in 10% of the United States population, and results in distinct absolute neutrophil counts (ANC) and white blood cell count (WBC) RIs. Investigators from twenty-three institutions completed a collaborative assessment of ANC and WBC in healthy Duffy-null pediatric and adult participants. This report summarizes a roadmap for developing and implementing Duffy-null RIs and infrastructure. Through consensus, we identified the following key themes: 1) Identifying Stakeholders and Funding, 2) Collecting Samples, 3) Testing for Duffy Status, 4) Implementing Duffy-Specific Policies and Tools, and 5) Educating Providers and Duffy-null individuals. Across themes, we outline challenges and opportunities relevant to the development and implementation of Duffy-null infrastructure. We provide examples from community and academic practice settings as well as sites with geographic, size, funding, and population diversity. This roadmap will support healthcare systems, hospitals, and laboratories in developing and implementing Duffy-specific infrastructure.
- Open Access
- 5 November 2026
- Published by American Society of Hematology in Blood Advances
Establishing Absolute Neutrophil Count and White Blood Cell Count Reference Intervals for the Duffy Null Population
Most reference intervals (RI) for absolute neutrophil count (ANC) and white blood cell count (WBC) in the United States (US) are not representative of people with the Duffy null phenotype (10% of the US population), which leads to misdiagnoses and inequity in care. We aimed to verify the adult Duffy null ANC RI and develop WBC and ANC RIs for pediatrics. 1,412 healthy Duffy null participants from 23 sites were included. All sites agreed on eligibility criteria. Otherwise, this was a pragmatic design with site-specific variation in collection approach. ANC and WBC were stratified into 5 age categories: 6 months-2 years, 3-6 years, 7-12 years, 13-17 years, and 18+ years. RI were calculated by Clinical and Laboratory Standards Institute guidelines. Duffy null-specific ANC RI were 0.53-4.50×109/L (6 months-2 years, n=184), 0.78-4.67×109/L (3-6 years, n=160), 0.87-5.34×109/L (7-12 years, n=190), 0.90-4.89×109/L (13-17 years, n=216), and 1.03-7.30×109/L (18+ years, n=662). 25% of adults had ANC <2.00×109/L and 24-53% of children had ANC <1.50×109/L. Sensitivity analyses did not show any significant differences in ANC RI when accounting for blood draw type, setting, collection site, hematology analyzer, or hemoglobin and platelet counts. This study provides the first report of Duffy null-specific pediatric ANC and WBC RI, as well as a large-scale verification of adult Duffy null-specific ANC and WBC RI. Adoption of Duffy null-specific RIs is necessary for the accurate interpretation of laboratory values that will support appropriate and equitable medical decision-making.
- 5 November 2026
- Published by American Society of Hematology in Blood Advances
Open AccessEstablishing Absolute Neutrophil Count and White Blood Cell Count Reference Intervals for the Duffy Null Population
Most reference intervals (RI) for absolute neutrophil count (ANC) and white blood cell count (WBC) in the United States (US) are not representative of people with the Duffy null phenotype (10% of the US population), which leads to misdiagnoses and inequity in care. We aimed to verify the adult Duffy null ANC RI and develop WBC and ANC RIs for pediatrics. 1,412 healthy Duffy null participants from 23 sites were included. All sites agreed on eligibility criteria. Otherwise, this was a pragmatic design with site-specific variation in collection approach. ANC and WBC were stratified into 5 age categories: 6 months-2 years, 3-6 years, 7-12 years, 13-17 years, and 18+ years. RI were calculated by Clinical and Laboratory Standards Institute guidelines. Duffy null-specific ANC RI were 0.53-4.50×109/L (6 months-2 years, n=184), 0.78-4.67×109/L (3-6 years, n=160), 0.87-5.34×109/L (7-12 years, n=190), 0.90-4.89×109/L (13-17 years, n=216), and 1.03-7.30×109/L (18+ years, n=662). 25% of adults had ANC <2.00×109/L and 24-53% of children had ANC <1.50×109/L. Sensitivity analyses did not show any significant differences in ANC RI when accounting for blood draw type, setting, collection site, hematology analyzer, or hemoglobin and platelet counts. This study provides the first report of Duffy null-specific pediatric ANC and WBC RI, as well as a large-scale verification of adult Duffy null-specific ANC and WBC RI. Adoption of Duffy null-specific RIs is necessary for the accurate interpretation of laboratory values that will support appropriate and equitable medical decision-making.
- Open Access
- 15 January 2026
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 3 (1)
Trajectories of emergency department use among adolescents and young adults with sickle cell disease in North Carolina
Objectives: Emergency department (ED) utilization among transition age adolescents and young adults (AYAs, 14-30 years old) with SCD is linked to morbidity and mortality. We describe age-related ED utilization and associations with sociodemographic characteristics among AYAs with SCD in North Carolina (NC). Methods: This observational study used the NC Hospital Discharge data (2014-2019). We conducted latent growth class analysis to identify distinct ED utilization trajectories by age and bivariate analyses to explore associations between ED utilization classes and sociodemographic factors. Results: During the study, 3614 AYAs with SCD (54% female; 96% Black) had 39 585 ED visits. The mean number of annual ED visits was 1.23 at age 14, peaking at 5.35 at age 24, and declining to 4.64 at age 30. Three classes of ED utilization trajectories were identified: low [95.2%, mean (SD) annual visits = 2.29 (2.55)], medium [4.1%, mean (SD) annual visits = 20.38 (7.42)], and high [0.7%, mean (SD) annual visits = 47.71 (18.58)]. Despite similar utilization at age 14, medium and high utilization groups had respectively 10 and 20 times the ED utilization of the low utilization group and had visits at multiple EDs. Social vulnerability was not associated with ED utilization. Conclusion: A small fraction of AYAs drive most ED utilization, with significant increases observed during transition. These results underscore the necessity for resources and tailored interventions to enhance care continuity during transition. Further research should identify modifiable factors influencing ED visits and develop strategies to improve transition care.
- 15 January 2026
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 3 (1)
Open AccessTrajectories of emergency department use among adolescents and young adults with sickle cell disease in North Carolina
Objectives: Emergency department (ED) utilization among transition age adolescents and young adults (AYAs, 14-30 years old) with SCD is linked to morbidity and mortality. We describe age-related ED utilization and associations with sociodemographic characteristics among AYAs with SCD in North Carolina (NC). Methods: This observational study used the NC Hospital Discharge data (2014-2019). We conducted latent growth class analysis to identify distinct ED utilization trajectories by age and bivariate analyses to explore associations between ED utilization classes and sociodemographic factors. Results: During the study, 3614 AYAs with SCD (54% female; 96% Black) had 39 585 ED visits. The mean number of annual ED visits was 1.23 at age 14, peaking at 5.35 at age 24, and declining to 4.64 at age 30. Three classes of ED utilization trajectories were identified: low [95.2%, mean (SD) annual visits = 2.29 (2.55)], medium [4.1%, mean (SD) annual visits = 20.38 (7.42)], and high [0.7%, mean (SD) annual visits = 47.71 (18.58)]. Despite similar utilization at age 14, medium and high utilization groups had respectively 10 and 20 times the ED utilization of the low utilization group and had visits at multiple EDs. Social vulnerability was not associated with ED utilization. Conclusion: A small fraction of AYAs drive most ED utilization, with significant increases observed during transition. These results underscore the necessity for resources and tailored interventions to enhance care continuity during transition. Further research should identify modifiable factors influencing ED visits and develop strategies to improve transition care.
- 26 August 2025
- Published by Wiley in Pediatric Blood & Cancer
- p. e31963
Virtual Transition Assessments in Sickle Cell Disease Are Feasible and Available Transition Instruments May Highlight Different Components of the Transition Experience
There is increased morbidity and mortality during the transition to adult care in sickle cell disease. Standardized implementation of validated transition tools may improve readiness for transition (RFT). We tested the impact of telehealth on this process by comparing in‐person or via telehealth administration of the provider‐administered tool, TRxANSITION Index (TI), to the patient‐reported tool, transition intervention program‐RFT (TIP‐RFT) in patients 15–21 years old. Scores between testing given in person or via telehealth did not differ (p > 0.9, N = 20). TIP‐RFT scores were up to 14% higher than TI. Our results indicate that telehealth transition tools are feasible and are acceptable to providers and participants. Our data also suggest that the more objective TI may be most sensitive in detecting transition needs; this awaits validation.
- 26 August 2025
- Published by Wiley in Pediatric Blood & Cancer
- p. e31963
Virtual Transition Assessments in Sickle Cell Disease Are Feasible and Available Transition Instruments May Highlight Different Components of the Transition Experience
There is increased morbidity and mortality during the transition to adult care in sickle cell disease. Standardized implementation of validated transition tools may improve readiness for transition (RFT). We tested the impact of telehealth on this process by comparing in‐person or via telehealth administration of the provider‐administered tool, TRxANSITION Index (TI), to the patient‐reported tool, transition intervention program‐RFT (TIP‐RFT) in patients 15–21 years old. Scores between testing given in person or via telehealth did not differ (p > 0.9, N = 20). TIP‐RFT scores were up to 14% higher than TI. Our results indicate that telehealth transition tools are feasible and are acceptable to providers and participants. Our data also suggest that the more objective TI may be most sensitive in detecting transition needs; this awaits validation.
- Open Access
- 4 August 2025
- Published by Elsevier in Blood Red Cells & Iron
- Vol. 1 (3)
Red cell physiologic stress results in lower quality transfusions: a randomized trial in adults with sickle cell disease
- 4 August 2025
- Published by Elsevier in Blood Red Cells & Iron
- Vol. 1 (3)
Open AccessRed cell physiologic stress results in lower quality transfusions: a randomized trial in adults with sickle cell disease
- 25 May 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (1) , 217-224
Real‐world assessment of acute red cell exchange for stroke in sickle cell disease
Summary: Cerebrovascular accidents (CVA) are one of the most devastating complications in sickle cell disease (SCD). Chronic transfusion therapy has been established for primary and secondary prevention of CVA in SCD, resulting in a notable reduction in CVA incidence. For individuals with SCD presenting with CVA, the impact of acute management on neurological outcomes is not well studied. Herein, we examine the neurological outcomes of 29 children and adults with SCD who received acute red cell exchange (RCE) as primary therapy for neurological events at a single institution. Twelve (41%) individuals had a prior history of CVA, and 12 (41%) were on chronic transfusions. Among 13 adults, 3 (23%) had a history of diabetes and 4 (31%) had a history of hypertension. One adult (7.7%) received thrombolytic therapy; the remainder were ineligible due to age, timing of presentation, intracranial haemorrhage or transient symptoms. Higher post‐RCE haematocrit was associated with decreased odds of death or persistent neurological symptoms at hospital discharge (OR 0.69, 95% CI: 0.45–0.94, p = 0.017). Optimal acute management of adults living with SCD presenting with CVA remains an understudied yet important topic. Future prospective studies may determine how best to tailor acute management to improve neurological outcomes.
- 25 May 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (1) , 217-224
Real‐world assessment of acute red cell exchange for stroke in sickle cell disease
Summary: Cerebrovascular accidents (CVA) are one of the most devastating complications in sickle cell disease (SCD). Chronic transfusion therapy has been established for primary and secondary prevention of CVA in SCD, resulting in a notable reduction in CVA incidence. For individuals with SCD presenting with CVA, the impact of acute management on neurological outcomes is not well studied. Herein, we examine the neurological outcomes of 29 children and adults with SCD who received acute red cell exchange (RCE) as primary therapy for neurological events at a single institution. Twelve (41%) individuals had a prior history of CVA, and 12 (41%) were on chronic transfusions. Among 13 adults, 3 (23%) had a history of diabetes and 4 (31%) had a history of hypertension. One adult (7.7%) received thrombolytic therapy; the remainder were ineligible due to age, timing of presentation, intracranial haemorrhage or transient symptoms. Higher post‐RCE haematocrit was associated with decreased odds of death or persistent neurological symptoms at hospital discharge (OR 0.69, 95% CI: 0.45–0.94, p = 0.017). Optimal acute management of adults living with SCD presenting with CVA remains an understudied yet important topic. Future prospective studies may determine how best to tailor acute management to improve neurological outcomes.
- 17 January 2025
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 2 (1) , yoaf040
International variations in body mass index within the CASiRe global cohort of sickle cell disease patients
Objectives: Although SCD has traditionally been associated with underweight status, body mass index (BMI) status is shifting globally. As disease-modifying therapies have become available, BMI status has increased. Our aim was to determine the prevalence and risk factors of underweight, overweight, and obese statuses in SCD patients in low-middle and high-income countries. Methods: The CASiRe research consortium cross-sectionally analyzed the association of BMI status (underweight, normal weight, overweight, and obesity) to age, genotype, treatment status, and associated clinical outcomes of 532 SCD patients from Italy, United States, and Ghana. Results: Overall, BMI status varied significantly between countries (underweight P < .001, obesity P < .001, overweight P = .038). Underweight (9.5%-17.2%) and overweight/obesity (14%-27.8%) statuses increased from pediatrics to adults. Hemoglobin (Hgb) SC represented the highest percentage of overweight/obese patients (Hgb SC 49% vs SS/SB0Thal 16%, P < .001). Hydroxyurea use (HgbSS/SB0Thal [-]Hydroxyurea 11% vs [+]Hydroxyurea 32% overweight/obese, P < .001), higher hemoglobin levels (Adults, R = 0.396 P < .001), and genotype (HgbSS/SB0Thal vs SC, P < .001) correlated with overweight/obesity status. Lower hemoglobin (OR 0.77, P < .001) and male sex (OR 0.41 P < .001) were predictors of underweight status while higher hemoglobin (OR 1.38, P < .001) and older age (OR 1.01, P = .031) were predictors of obesity. Underweight status was associated with Ghanian site, male gender, leg ulcers, and microalbuminuria showing that it remains a significant clinical issue. Conclusions: As access to disease-modifying therapy improves for SCD, monitoring for overweight and obesity and their comorbid conditions may be necessary. Underweight SCD patients should be carefully evaluated for end-organ complications, especially in low-resource settings.
- 17 January 2025
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 2 (1) , yoaf040
International variations in body mass index within the CASiRe global cohort of sickle cell disease patients
Objectives: Although SCD has traditionally been associated with underweight status, body mass index (BMI) status is shifting globally. As disease-modifying therapies have become available, BMI status has increased. Our aim was to determine the prevalence and risk factors of underweight, overweight, and obese statuses in SCD patients in low-middle and high-income countries. Methods: The CASiRe research consortium cross-sectionally analyzed the association of BMI status (underweight, normal weight, overweight, and obesity) to age, genotype, treatment status, and associated clinical outcomes of 532 SCD patients from Italy, United States, and Ghana. Results: Overall, BMI status varied significantly between countries (underweight P < .001, obesity P < .001, overweight P = .038). Underweight (9.5%-17.2%) and overweight/obesity (14%-27.8%) statuses increased from pediatrics to adults. Hemoglobin (Hgb) SC represented the highest percentage of overweight/obese patients (Hgb SC 49% vs SS/SB0Thal 16%, P < .001). Hydroxyurea use (HgbSS/SB0Thal [-]Hydroxyurea 11% vs [+]Hydroxyurea 32% overweight/obese, P < .001), higher hemoglobin levels (Adults, R = 0.396 P < .001), and genotype (HgbSS/SB0Thal vs SC, P < .001) correlated with overweight/obesity status. Lower hemoglobin (OR 0.77, P < .001) and male sex (OR 0.41 P < .001) were predictors of underweight status while higher hemoglobin (OR 1.38, P < .001) and older age (OR 1.01, P = .031) were predictors of obesity. Underweight status was associated with Ghanian site, male gender, leg ulcers, and microalbuminuria showing that it remains a significant clinical issue. Conclusions: As access to disease-modifying therapy improves for SCD, monitoring for overweight and obesity and their comorbid conditions may be necessary. Underweight SCD patients should be carefully evaluated for end-organ complications, especially in low-resource settings.
- 7 December 2024
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (12) , 5235-5239
Livedoid vasculopathy in hemoglobinopathy-associated chronic leg ulcers
Chronic leg ulceration is a debilitating manifestation of hemoglobinopathies, and best management is uncertain. Livedoid vasculopathy (LV) is a cutaneous non-inflammatory thrombotic vasculopathy treated with anticoagulation that has been identified in hemoglobinopathy-associated chronic leg ulceration. However, most patients with hemoglobinopathy-associated ulcers do not undergo workup for secondary causes, and the prevalence and relevance of LV is unclear. Outcomes of secondary workup were examined retrospectively in this study. 108 patients with hemoglobinopathy-associated chronic leg ulcers were identified. 15% of patients underwent skin biopsy, and 97% of biopsies showed non-specific findings. Two patients had LV and neither responded to anticoagulants. Livedoid vasculopathy is a rare cause of ulceration in hemoglobin gene disorders and the benefit of anticoagulation in these cases is unclear.
- 7 December 2024
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (12) , 5235-5239
Livedoid vasculopathy in hemoglobinopathy-associated chronic leg ulcers
Chronic leg ulceration is a debilitating manifestation of hemoglobinopathies, and best management is uncertain. Livedoid vasculopathy (LV) is a cutaneous non-inflammatory thrombotic vasculopathy treated with anticoagulation that has been identified in hemoglobinopathy-associated chronic leg ulceration. However, most patients with hemoglobinopathy-associated ulcers do not undergo workup for secondary causes, and the prevalence and relevance of LV is unclear. Outcomes of secondary workup were examined retrospectively in this study. 108 patients with hemoglobinopathy-associated chronic leg ulcers were identified. 15% of patients underwent skin biopsy, and 97% of biopsies showed non-specific findings. Two patients had LV and neither responded to anticoagulants. Livedoid vasculopathy is a rare cause of ulceration in hemoglobin gene disorders and the benefit of anticoagulation in these cases is unclear.
- Open Access
- 14 November 2024
- Published by Impact Journals, LLC in Aging
- Vol. null (21) , 13225-13236
Adolescents and young adults with sickle cell disease exhibit accelerated aging with elevated T-cell p16INK4a expression
People living with sickle cell disease (SCD) experience complications indicative of an accelerated aging phenotype typified by early decline in physical function and increased risk for age-related conditions. Cellular senescence, measured by expression of p16INK4a in peripheral T-lymphocytes, is recognized as one of the underlying contributors to organismal aging. To examine if cellular senescence is increased in SCD patients, we cross-sectionally measured and compared expression of p16 mRNA in peripheral blood T lymphocytes in 18 adolescents and young adults with SCD to 27 similarly aged individuals without SCD. Expression of p16 was dramatically higher in individuals with SCD vs. without SCD (10.1 vs. 8.7 log2 p16 units, respectively, p < 0.001) - a gap of 43 years in biological age - consistent with accelerated aging in the SCD population. Race was not associated with the increased p16 expression in the SCD group. These initial results suggest that individuals with SCD have a significantly higher cellular senescence burden which may contribute to premature aging, physiological decline, and excess morbidities. Additional longitudinal assessment and consideration for trials of senolytic therapies among individuals living with SCD and high p16 expression are warranted to improve their health span.
- 14 November 2024
- Published by Impact Journals, LLC in Aging
- Vol. null (21) , 13225-13236
Open AccessAdolescents and young adults with sickle cell disease exhibit accelerated aging with elevated T-cell p16INK4a expression
People living with sickle cell disease (SCD) experience complications indicative of an accelerated aging phenotype typified by early decline in physical function and increased risk for age-related conditions. Cellular senescence, measured by expression of p16INK4a in peripheral T-lymphocytes, is recognized as one of the underlying contributors to organismal aging. To examine if cellular senescence is increased in SCD patients, we cross-sectionally measured and compared expression of p16 mRNA in peripheral blood T lymphocytes in 18 adolescents and young adults with SCD to 27 similarly aged individuals without SCD. Expression of p16 was dramatically higher in individuals with SCD vs. without SCD (10.1 vs. 8.7 log2 p16 units, respectively, p < 0.001) - a gap of 43 years in biological age - consistent with accelerated aging in the SCD population. Race was not associated with the increased p16 expression in the SCD group. These initial results suggest that individuals with SCD have a significantly higher cellular senescence burden which may contribute to premature aging, physiological decline, and excess morbidities. Additional longitudinal assessment and consideration for trials of senolytic therapies among individuals living with SCD and high p16 expression are warranted to improve their health span.
- Open Access
- 27 August 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (16) , 4457-4458
Doubling down on PK activation for sickle cell disease
In this issue of Blood Advances, Saraf et al1 report the results of the phase 1 multicenter, randomized, placebo-controlled study of etavopivat, a pyruvate In this issue of Blood Advances, Saraf et al1 report the results of the phase 1 multicenter, randomized, placebo-controlled study of etavopivat, a pyruvate
- 27 August 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (16) , 4457-4458
Open AccessDoubling down on PK activation for sickle cell disease
In this issue of Blood Advances, Saraf et al1 report the results of the phase 1 multicenter, randomized, placebo-controlled study of etavopivat, a pyruvate In this issue of Blood Advances, Saraf et al1 report the results of the phase 1 multicenter, randomized, placebo-controlled study of etavopivat, a pyruvate